Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

The Egyptian Heart Journal

Table 3 Lab, echocardiographic data, and myocardial perfusion index (MPI) on admission

		EES group	BVS group	Test	p value	Sig.
		No. = 40	No. = 20	Test	p value	Sig.
Lab
Hemoglobin	Mean ± SD	13.5 ± 0.68	13.2 ± 0.89	1.448^b	0.153	NS
Hemoglobin	Range	12–14	12–14	1.448^b	0.153	NS
Creatinine	Mean ± SD	0.97 ± 0.13	0.99–0.08	− 0.639^b	0.525	NS
Creatinine	Range	0.4 – 1.2	0.8–1.2	− 0.639^b	0.525	NS
ECG	NAD	17 (42.5%)	7 (35.0%)	7.265^a	0.202	NS
	Poor R wave progression	3 (7.5%)	2 (10.0%)
	Q wave and inf.	7 (17.5%)	4 (20.0%)
	Q wave and ant.	8 (20.0%)	3 (15.0%)
	T inversion ant.	5 (12.5%)	1 (5.0%)
	LAHB	0 (0.0%)	3 (15.0%)
	NAD	17 (42.5%)	7 (35.0%)
Echo
EF (%)	Mean ± SD	57.55 ± 7.55	56.45 ± 11.11	0.453^b	0.652	NS
EF (%)	Range	45–73	40–85	0.453^b	0.652	NS
DD (grade)	I	1 (2.5%)	0 (0.0%)	0.508^a	0.476	NS
DD (grade)	II	39 (97.5%)	20 (100.0%)	0.508^a	0.476	NS
Wall motion	No	23 (57.5%)	10 (50.0%)	2.161^a	0.540	NS
	Anterior	13 (32.5%)	7 (35.0%)
	Inferior	4 (10.0%)	2 (10.0%)
	Lateral	0 (0.0%)	1 (5.0%)
MPI
Viable		13 (32.5%)	4 (20%)	2.063	0.840	NS
Ischemia anterior		5 (12.5%)	4 (20%)
Ischemia inferior		6 (15%)	5 (25%)
Ischemia lateral		2 (5%)	1 (5%)
Mixed scar anterior		7 (17.5%)	3 (15%)
Mixed scar inferior		7 (17.5%)	3 (15%)

^aChi-square test
^bIndependent t test, NS non-significant, S significant, CBC complete blood count, DD diastolic dysfunction, ECG electrogardiogram